Results 161 to 170 of about 22,180 (202)
Some of the next articles are maybe not open access.
Nature Reviews Drug Discovery, 2003
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of aripiprazole are discussed. Aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia.
Michelle A, Grady +2 more
+6 more sources
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of aripiprazole are discussed. Aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia.
Michelle A, Grady +2 more
+6 more sources
Reactions Weekly, 2013
Aripiprazole is an atypical antipsychotic drug which belongs to the benzisoxazole derivatives. Aripiprazole is available in many salts and polymorphs forms. X-ray diffraction, IR spectroscopy, and DSC could be used for differentiating the polymorphs of aripiprazole. Some instrumental methods of analysis such as UV spectrophotometer, HPTLC, HPLC, and CE
Febry, Ardiana +2 more
openaire +3 more sources
Aripiprazole is an atypical antipsychotic drug which belongs to the benzisoxazole derivatives. Aripiprazole is available in many salts and polymorphs forms. X-ray diffraction, IR spectroscopy, and DSC could be used for differentiating the polymorphs of aripiprazole. Some instrumental methods of analysis such as UV spectrophotometer, HPTLC, HPLC, and CE
Febry, Ardiana +2 more
openaire +3 more sources
Pediatric Drugs, 2007
Aripiprazole is a novel atypical antipsychotic that is approved in the US for use in adolescents with schizophrenia. In adolescents with schizophrenia, oral aripiprazole 10 or 30 mg/day lead to significantly greater reductions than placebo in the Positive and Negative Syndrome Scale (PANSS) total score from baseline to 6 weeks, according to findings ...
Mark, Sanford, Gillian M, Keating
+6 more sources
Aripiprazole is a novel atypical antipsychotic that is approved in the US for use in adolescents with schizophrenia. In adolescents with schizophrenia, oral aripiprazole 10 or 30 mg/day lead to significantly greater reductions than placebo in the Positive and Negative Syndrome Scale (PANSS) total score from baseline to 6 weeks, according to findings ...
Mark, Sanford, Gillian M, Keating
+6 more sources
CNS Drugs, 2002
Aripiprazole is a quinolinone derivative and the first of a new class of atypical antipsychotics. The drug has partial agonist activity at dopamine D(2) and serotonin 5-HT(1A) receptors, and is also an antagonist at 5-HT(2A) receptors. In patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least
Jane K, McGavin, Karen L, Goa
openaire +2 more sources
Aripiprazole is a quinolinone derivative and the first of a new class of atypical antipsychotics. The drug has partial agonist activity at dopamine D(2) and serotonin 5-HT(1A) receptors, and is also an antagonist at 5-HT(2A) receptors. In patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least
Jane K, McGavin, Karen L, Goa
openaire +2 more sources
Annals of Clinical Psychiatry, 2006
Delirium is a common condition frequently seen in consultation-liaison psychiatry. It is especially common among medically compromised patients and is an indicator of the severity of the medical illness. In addition, it is associated with a higher morbidity, mortality or longer hospitalization. Traditionally, haloperidol has been used to treat delirium-
Adekola O, Alao, Lindsay, Moskowitz
openaire +2 more sources
Delirium is a common condition frequently seen in consultation-liaison psychiatry. It is especially common among medically compromised patients and is an indicator of the severity of the medical illness. In addition, it is associated with a higher morbidity, mortality or longer hospitalization. Traditionally, haloperidol has been used to treat delirium-
Adekola O, Alao, Lindsay, Moskowitz
openaire +2 more sources
International Clinical Psychopharmacology, 2006
Cases of psychotic symptoms that worsen after treatment with aripiprazole have been described. We report the case of a 19-year-old patient who, although her psychotic symptoms did not worsen, attempted suicide after switching from risperidone to aripiprazole.
Laurent, Holzer, Chin B, Eap
openaire +2 more sources
Cases of psychotic symptoms that worsen after treatment with aripiprazole have been described. We report the case of a 19-year-old patient who, although her psychotic symptoms did not worsen, attempted suicide after switching from risperidone to aripiprazole.
Laurent, Holzer, Chin B, Eap
openaire +2 more sources
Aripiprazole for schizophrenia
Cochrane Database of Systematic Reviews, 2003Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond to these older antipsychotics and more people experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal ...
H G, El-Sayeh, C, Morganti
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2005
Aripiprazole is a new chemical entity with a unique pharmacological profile. It has strong affinities for certain dopamine receptors, and intermediate affinity for serotonin, adrenergic and histamine receptors. Partial agonism of the D2 dopamine and 5HT1A serotonin receptors, and antagonism of the 5HT2 serotonin receptor are believed to be the ...
openaire +2 more sources
Aripiprazole is a new chemical entity with a unique pharmacological profile. It has strong affinities for certain dopamine receptors, and intermediate affinity for serotonin, adrenergic and histamine receptors. Partial agonism of the D2 dopamine and 5HT1A serotonin receptors, and antagonism of the 5HT2 serotonin receptor are believed to be the ...
openaire +2 more sources